Both gumokimab and manfidokimab met their primary endpoints, as Akeso oversees NDAs with the NMPA for both drugs.

WCG has introduced Total Training, a clinical trial solution designed to reduce protocol deviations and enhance site ...

Coya Therapeutics has announced the acceptance by the US FDA of IND application for COYA 302, paving the way for a Phase II ...

BlossomHill Therapeutics has dosed the first subject in the expansion cohorts of the SOLARA Phase I/II trial to evaluate ...

The long-term data supports the drug’s progression into the HEALEY ALS Platform trial, with NUZ-001 dosing set to commence in ...

The FDA has announced it will no longer accept clinical trials that involve sending US patients cells from US to China for ...

Tyra Biosciences has dosed the first paediatric participant in the dose-escalation/dose-expansion Phase II BEACH301 trial of ...

If approved, AbbVie's Rinvoq could be set to dominate the alopecia market after exhibiting better efficacy than main ...

As regulators push to phase out animal testing, Charles River’s Steve Bulera notes that widespread implementation of ...

Dynavax has revealed outcomes from the initial part of its Phase I/II trial, comparing its shingles vaccine Z-1018 against ...

This webinar offers essential tools and insights to help organisations confidently navigate the BioSecure Act, ensuring they ...

Reunion Neuroscience will be advancing its psychedelic therapy RE104 to a Phase III trial in post-partum depression (PPD) in ...